223 related articles for article (PubMed ID: 20210733)
1. Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population.
Efrati E; Elkin H; Sprecher E; Krivoy N
Curr Drug Saf; 2010 Jul; 5(3):190-3. PubMed ID: 20210733
[TBL] [Abstract][Full Text] [Related]
2. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
Scott SA; Edelmann L; Kornreich R; Desnick RJ
Am J Hum Genet; 2008 Feb; 82(2):495-500. PubMed ID: 18252229
[TBL] [Abstract][Full Text] [Related]
3. Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians.
Nahar R; Deb R; Saxena R; Puri RD; Verma IC
Pharmacol Rep; 2013; 65(1):187-94. PubMed ID: 23563037
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.
Kwon A; Jo SH; Im HJ; Jo YA; Park JY; Kang HJ; Kim HS; Cho HC; Lee YK
J Thromb Thrombolysis; 2011 Nov; 32(4):467-73. PubMed ID: 21713378
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
[TBL] [Abstract][Full Text] [Related]
6. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
[TBL] [Abstract][Full Text] [Related]
7. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
[TBL] [Abstract][Full Text] [Related]
8. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
[TBL] [Abstract][Full Text] [Related]
9. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran.
Azarpira N; Namazi S; Hendijani F; Banan M; Darai M
Pharmacol Rep; 2010; 62(4):740-6. PubMed ID: 20885015
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population.
Djaffar-Jureidini I; Chamseddine N; Keleshian S; Naoufal R; Zahed L; Hakime N
Genet Test Mol Biomarkers; 2011 Nov; 15(11):827-30. PubMed ID: 21651319
[TBL] [Abstract][Full Text] [Related]
11. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T; Miyata T
Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
[TBL] [Abstract][Full Text] [Related]
12. [Distribution of variant alleles association with warfarin pharmacokinetics and pharmacodynamics in the Han population in China].
Liu Y; Zhong SL; Yang M; Tan HH; Fei HW; Chen JY; Yu XY; Lin SG
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Dec; 43(6):798-803. PubMed ID: 22178823
[TBL] [Abstract][Full Text] [Related]
13. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
[TBL] [Abstract][Full Text] [Related]
14. New genetic variant that might improve warfarin dose prediction in African Americans.
Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
[TBL] [Abstract][Full Text] [Related]
15. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
[TBL] [Abstract][Full Text] [Related]
16. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
[TBL] [Abstract][Full Text] [Related]
18. Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia.
Alzahrani AM; Ragia G; Hanieh H; Manolopoulos VG
Biomed Res Int; 2013; 2013():315980. PubMed ID: 23586031
[TBL] [Abstract][Full Text] [Related]
19. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes.
Zhu Y; Shennan M; Reynolds KK; Johnson NA; Herrnberger MR; Valdes R; Linder MW
Clin Chem; 2007 Jul; 53(7):1199-205. PubMed ID: 17510308
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.
Duconge J; Cadilla CL; Windemuth A; Kocherla M; Gorowski K; Seip RL; Bogaard K; Renta JY; Piovanetti P; D'Agostino D; Santiago-Borrero PJ; Ruaño G
Ethn Dis; 2009; 19(4):390-5. PubMed ID: 20073138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
